Fresenius


A first glimpse of the ‘lighter’ Fresenius

20/11/23 -"We have made a first round of adjustments ‘ranking out’ FMC’s contributions to Fresenius’ financial framework. As there is not much information available, we have had to make numerous assumptions and ..."

Pages
57
Language
English
Published on
20/11/23
You may also be interested by these reports :
06/12/23
Coloplast reported Q4 23 organic revenue growth of 8% as a strong performance in Voice & Respiratory and Ostomy was partially offset by a weaker ...

06/12/23
To account for the material impact from FX headwinds, we have revised down our near-term estimates. Nonetheless, the firm’s operational performance ...

06/12/23
Fresenius has decided to accept the €300m (of which ~70m had already been taken) from the German government, which is the relief package to ...

01/12/23
We have maintained our assumption and the company’s plan of a €300m capital increase to be completed in H1 24, but with an expected subscription ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO